Logo

FTII

FutureTech II Acquisition Corp.

FTII

FutureTech II Acquisition Corp. • NASDAQ
$12.02 ▲ 0.00% (+0.00)
Market Cap $51.57 M
52w High $14.00
52w Low $10.52
Dividend Yield 0%
P/E -28.62
Volume 1
Outstanding Shares 4.29M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $138.735K ▼ $-80.647K ▲ 0% $-0.023 ▲ $-138.735K ▲
Q1-2025 $0 $453.835K ▼ $-290K ▲ 0% $-0.083 ▲ $-454K ▲
Q4-2024 $0 $801.918K ▲ $-709K ▼ 0% $-0.28 ▼ $-851.919K ▼
Q3-2024 $0 $367.118K ▲ $-123K ▼ 0% $-0.035 ▼ $-367K ▼
Q2-2024 $0 $284.894K $-44.457K 0% $-0.013 $-284.894K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $160.723K ▲ $10.58M ▼ $10.381M ▼ $199.389K ▼
Q1-2025 $130.58K ▲ $11.066M ▼ $10.786M ▼ $280.036K ▲
Q4-2024 $56.768K ▲ $28.12M ▼ $27.894M ▲ $226.071K ▼
Q3-2024 $1.883K ▲ $28.496M ▲ $9.651M ▲ $18.844M ▼
Q2-2024 $476 $27.456M $6.077M $21.379M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-80.647K ▲ $-734.049K ▼ $-40.832K ▼ $805.024K ▲ $30.143K ▼ $-734.049K ▼
Q1-2025 $-289.673K ▲ $-453.155K ▲ $17.627M ▲ $-17.1M ▼ $73.812K ▲ $-453.155K ▲
Q4-2024 $-708.948K ▼ $-1.091M ▼ $720.665K ▲ $425K ▲ $57.885K ▲ $-1.091M ▼
Q3-2024 $-123.124K ▼ $-243.393K ▲ $15.4K ▲ $229.4K ▼ $1.407K ▲ $-243.393K ▲
Q2-2024 $-44.457K $-309.328K $-150K $459.391K $63 $-309.328K

Five-Year Company Overview

Income Statement

Income Statement FutureTech II has effectively been a shell company, so its income statement does not reflect a normal operating business. It shows no revenue and any reported earnings per share mainly come from SPAC mechanics, such as changes in warrant values, interest on trust cash, and listing costs. These figures are accounting outcomes rather than sustainable profits from products or services. As a result, the historical income statement provides almost no insight into how the merged Longevity Biomedical business might perform once it is operating as a biopharma company.

Balance Sheet

Balance Sheet The balance sheet is very light and typical of a SPAC nearing or going through a merger: small asset levels, minimal or no recorded cash here, no debt, and limited equity. The key economic value historically sat in the SPAC’s trust account, which is not visible in this simple snapshot. After the merger, the balance sheet will likely change dramatically, with a larger equity base tied to Longevity Biomedical’s assets and a focus on funding clinical programs. The true risk profile will depend on how much cash the combined company has after redemptions and capital raises, and on its ability to avoid taking on burdensome debt as it funds R&D.

Cash Flow

Cash Flow Reported cash flow is essentially flat, which is expected because FutureTech II has not run an operating business. Any real movements historically were related to the SPAC structure—trust funding, transaction expenses, and redemptions—rather than ongoing cash generation. Once Longevity Biomedical is in place, investors should expect negative operating cash flow for some time, as the company will likely spend heavily on clinical trials and development without meaningful revenue. The key question will be whether the company can secure enough funding, on reasonable terms, to support its pipeline through key milestones.

Competitive Edge

Competitive Edge As a stand‑alone SPAC, FutureTech II has no products, customers, or market share, so it has no inherent competitive position. The story shifts entirely to Longevity Biomedical, which will inherit the listing and operate in the longevity and regenerative medicine space. Its emerging position is built around several late‑stage or near‑late‑stage assets in stroke, soft tissue reconstruction, eye diseases, and corneal replacement—areas with clear unmet medical needs. Potential advantages include differentiated technology (especially therapeutic ultrasound and regenerative biomaterials), assets that are further along in clinical development than early discovery projects, and a strategy to acquire additional promising programs. The main competitive risks are clinical failure, rival therapies from larger biopharma players, and the need to continually raise capital to keep pace with better‑funded competitors.

Innovation and R&D

Innovation and R&D FutureTech II itself has no R&D; its value is tied to Longevity Biomedical’s pipeline after the merger. Longevity Biomedical is focused on innovative approaches: ultrasound‑based treatments for stroke and retinal vein issues, a regenerative biomaterial for soft tissue repair, and a biosynthetic cornea aimed at easing donor shortages. These are not incremental products; they attempt to solve important medical problems in new ways, which can be powerful if the science holds up and regulators approve them. The company’s strategy of acquiring late‑stage or near‑late‑stage programs reduces some early research risk but concentrates exposure on a few key clinical outcomes. Going forward, the strength of its patent protection, the quality and timing of clinical data, and its ability to continue sourcing and integrating new technologies will be critical for sustaining any innovation edge.

Summary

The historical financials of FTII mainly reflect a SPAC structure and offer little guidance on the future operating performance of the merged Longevity Biomedical business. There is no history of revenue, profitability, or operating cash flow to analyze in the usual way because the company has not yet run a commercial enterprise. The core of the story now is a transition to a clinical‑stage biopharma platform, with a diversified but still relatively concentrated pipeline in areas of high unmet medical need. This brings substantial scientific, regulatory, and financing risk, but also the possibility of outsized impact if key programs succeed. The most important things to monitor post‑merger will be: the final capital structure and cash runway, progress and results from pivotal and mid‑stage clinical trials, any new acquisitions or pipeline expansions, and how the company navigates competition in stroke, regenerative medicine, and ophthalmology.